Bazarbashi, Shouki
De Vol, Edward B.
Maraiki, Fatma
Al-Jedai, Ahmed
Ali, Afshan A.
Alhammad, Ali M.
Aljuffali, Ibrahim A.
Iskedjian, Michael
Funding for this research was provided by:
Pfizer
Bristol-Myers Squibb
Sanofi
Bayer
Article History
First Online: 14 April 2020
Compliance with Ethical Standards
:
: This study was sponsored by the King Faisal Specialist Hospital and Research Centre, through Grants from Pfizer, Bristol-Myers Squibb, Sanofi, and Bayer. The authors retained the right to publish, regardless of results and without censorship of the manuscript by the granting parties. Results of this study do not present any known or perceived bias, as no drug or product manufactured or marketed by the granting parties were the subject of analyses.
: This study was approved by the ethics review board of King Faisal Specialist Hospital and Research Centre, Riyadh, KSA, and was performed in accordance with the ethical standards of the Declaration of Helsinki.
: All study participants signed informed consent prior to starting the survey. Participants could withdraw from the study at any point during the survey.
: Drs. Bazarbashi, De Vol, Maraiki, Al-Jedai and Ali are employed by KFHSRC. Dr. Alhammad was, at the time of analysis, employed by National Guard Health Affairs, King Abdulaziz Medical City. Dr. Aljuffali is employed by King Saud University. Michael Iskedjian is the owner of PharmIdeas USA Inc., an independent research and consulting firm in the fields of health economics and outcomes research. Dr. Bazarbashi has received honoraria from, and/or has been on advisory boards for Pfizer, Bristol-Myers Squibb, Sanofi and Bayer. Michael Iskedjian has in the past performed studies for all four companies but reports no conflict at present time. None of the other co-authors report any conflict of interest.
: The dataset used for analyses is provided as supplementary material in the form of a Microsoft Excel file.